AstraZeneca Pharma gets DCGI nod to import, market prostate cancer drug Olaparib Film-coated tablets
Mumbai: Pharma major, AstraZeneca Pharma India Limited said that it has received Import and Market permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Olaparib Film-Coated tablets 100 mg and 150 mg - additional indication.Olaparib Film-Coated tablets 100 mg and 150 mg is additionally indicated as a monotherapy for the treatment of adult patients...
Login or Register to read the full article
Mumbai: Pharma major, AstraZeneca Pharma India Limited said that it has received Import and Market permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Olaparib Film-Coated tablets 100 mg and 150 mg - additional indication.
Olaparib Film-Coated tablets 100 mg and 150 mg is additionally indicated as a monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene mutations (germline and/or somatic) who have progressed following a prior new hormonal agent, company said in a filing with BSE.
The receipt of this Import and Market permission paves way for the launch of Olaparib FilmCoated Tablets 100 mg and 150 mg (Lynparza) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd